生长抑素类似物对糖尿病肾病大量蛋白尿的临床观察

Clinical Observation on Somatostatin Analogue in Massive Proteinuria of Diabetic Nephropathies

目的探讨生长抑素类似物对糖尿病肾病患者大量蛋白尿的临床观察。方法选取2015年1月—2017年5月收治的符合纳入标准的糖尿病肾病患者60例,随机分为研究组和对照组,各30例。对照组:予常规治疗;研究组:在常规治疗基础上加用生长抑素类似物奥曲肽。疗程为4周,观察治疗前后两组患者的尿蛋白定量、肾小球滤过率、低密度脂蛋白、血糖、糖化血红蛋白等疗效指标及不良反应情况。结果治疗4周后,研究组在尿蛋白定量、低密度脂蛋白、血糖、糖化血红蛋白等方面优于对照组(P<0.05)。结论生长抑素类似物奥曲肽在治疗糖尿病肾病大量蛋白尿方面,能显著降低患者尿蛋白、改善血糖、脂代谢异常,从而延缓肾功能进展,安全性较高。

Objective To study the clinical observation on somatostatin analogue in massive proteinuria of diabetic nephropathies. Methods 60 cases of patients with diabetic nephropathies meeting the inclusive standards from January 2015 to May 2017 were selected and randomly divided into two groups with 30 cases in each, the control group used the routine therapy, while the research group added the somatostatin analogue octreotide on the basis of the control group, and the curative effect was four weeks, and the curative effect indicators such as urinary protein quantitation, glomerular filtration rate,low density lipoprotein, blood glucose and glycosylated hemoglobin and adverse reactions before and after treatment were observed. Results In four weeks after treatment, the urinary protein quantification, low density lipoprotein, blood glucose and glycosylated hemoglobin in the research group were better than those in the control group（P〈0.05）. Conclusion The somatostatin analogue octreotide in massive proteinuria of diabetic nephropathies can obviously reduce the urine protein,and improve the abnorm al blood glucose and lipid metabolism thus prolonging the progression of renal function, and the safety is high.